Literature DB >> 28326542

Current and future therapies for addressing the effects of inflammation on HDL cholesterol metabolism.

Fatima Iqbal1, Wendy S Baker1, Madiha I Khan1, Shwetha Thukuntla1, Kevin H McKinney1, Nicola Abate1, Demidmaa Tuvdendorj1.   

Abstract

Cardiovascular disease (CVD) is a major cause of morbidity and mortality worldwide. Inflammatory processes arising from metabolic abnormalities are known to precipitate the development of CVD. Several metabolic and inflammatory markers have been proposed for predicting the progression of CVD, including high density lipoprotein cholesterol (HDL-C). For ~50 years, HDL-C has been considered as the atheroprotective 'good' cholesterol because of its strong inverse association with the progression of CVD. Thus, interventions to increase the concentration of HDL-C have been successfully tested in animals; however, clinical trials were unable to confirm the cardiovascular benefits of pharmaceutical interventions aimed at increasing HDL-C levels. Based on these data, the significance of HDL-C in the prevention of CVD has been called into question. Fundamental in vitro and animal studies suggest that HDL-C functionality, rather than HDL-C concentration, is important for the CVD-preventive qualities of HDL-C. Our current review of the literature positively demonstrates the negative impact of systemic and tissue (i.e. adipose tissue) inflammation in the healthy metabolism and function of HDL-C. Our survey indicates that HDL-C may be a good marker of adipose tissue health, independently of its atheroprotective associations. We summarize the current findings on the use of anti-inflammatory drugs to either prevent HDL-C clearance or improve the function and production of HDL-C particles. It is evident that the therapeutic agents currently available may not provide the optimal strategy for altering HDL-C metabolism and function, and thus, further research is required to supplement this mechanistic approach for preventing the progression of CVD. LINKED ARTICLES: This article is part of a themed section on Targeting Inflammation to Reduce Cardiovascular Disease Risk. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.22/issuetoc and http://onlinelibrary.wiley.com/doi/10.1111/bcp.v82.4/issuetoc.
© 2017 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28326542      PMCID: PMC5660004          DOI: 10.1111/bph.13743

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  256 in total

1.  Myeloperoxidase, inflammation, and dysfunctional high-density lipoprotein.

Authors:  Jonathan D Smith
Journal:  J Clin Lipidol       Date:  2010 Sep-Oct       Impact factor: 4.766

2.  Effects of low-dose aspirin on serum C-reactive protein and thromboxane B2 concentrations: a placebo-controlled study using a highly sensitive C-reactive protein assay.

Authors:  M Feldman; I Jialal; S Devaraj; B Cryer
Journal:  J Am Coll Cardiol       Date:  2001-06-15       Impact factor: 24.094

3.  Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity.

Authors:  Y Arita; S Kihara; N Ouchi; M Takahashi; K Maeda; J Miyagawa; K Hotta; I Shimomura; T Nakamura; K Miyaoka; H Kuriyama; M Nishida; S Yamashita; K Okubo; K Matsubara; M Muraguchi; Y Ohmoto; T Funahashi; Y Matsuzawa
Journal:  Biochem Biophys Res Commun       Date:  1999-04-02       Impact factor: 3.575

4.  Relationship among physical activity, sedentary behaviors, and cardiometabolic risk factors during gastric bypass surgery-induced weight loss.

Authors:  Jakob F Wefers; Tracey L Woodlief; Elvis A Carnero; Nicole L Helbling; Steven J Anthony; Gabriel S Dubis; John M Jakicic; Joseph A Houmard; Bret H Goodpaster; Paul M Coen
Journal:  Surg Obes Relat Dis       Date:  2016-08-26       Impact factor: 4.734

Review 5.  Translating molecular discoveries into new therapies for atherosclerosis.

Authors:  Daniel J Rader; Alan Daugherty
Journal:  Nature       Date:  2008-02-21       Impact factor: 49.962

6.  Raising HDL cholesterol without inducing hepatic steatosis and hypertriglyceridemia by a selective LXR modulator.

Authors:  Bowman Miao; Susan Zondlo; Sandy Gibbs; Debra Cromley; Vinayak P Hosagrahara; Todd G Kirchgessner; Jeffrey Billheimer; Ranjan Mukherjee
Journal:  J Lipid Res       Date:  2004-05-16       Impact factor: 5.922

7.  Metformin administration induces hepatotoxic effects in paraoxonase-1-deficient mice.

Authors:  Anabel García-Heredia; Marta Riera-Borrull; Isabel Fort-Gallifa; Fedra Luciano-Mateo; Noemí Cabré; Anna Hernández-Aguilera; Jorge Joven; Jordi Camps
Journal:  Chem Biol Interact       Date:  2016-03-03       Impact factor: 5.192

Review 8.  Lipid profile changes in patients with chronic inflammatory arthritis treated with biologic agents and tofacitinib in randomized clinical trials: a systematic review and meta-analysis.

Authors:  Alejandro Souto; Eva Salgado; José Ramón Maneiro; Antonio Mera; Loreto Carmona; Juan J Gómez-Reino
Journal:  Arthritis Rheumatol       Date:  2015-01       Impact factor: 10.995

9.  Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network.

Authors:  Mark W Russo; Jay H Hoofnagle; Jiezhun Gu; Robert J Fontana; Huiman Barnhart; David E Kleiner; Naga Chalasani; Herbert L Bonkovsky
Journal:  Hepatology       Date:  2014-05-13       Impact factor: 17.425

10.  Niacin inhibits vascular inflammation via downregulating nuclear transcription factor-κB signaling pathway.

Authors:  Yanhong Si; Ying Zhang; Jilong Zhao; Shoudong Guo; Lei Zhai; Shutong Yao; Hui Sang; Nana Yang; Guohua Song; Jue Gu; Shucun Qin
Journal:  Mediators Inflamm       Date:  2014-05-27       Impact factor: 4.711

View more
  9 in total

1.  Sex-dependent difference in the relationship between adipose-tissue cholesterol efflux and estradiol concentrations in young healthy humans.

Authors:  Fatima Iqbal; William J Durham; Ayyash Melhem; Saleem Raslan; Tony T Tran; Traver J Wright; Rabia Asghar; Ken Fujise; Elena Volpi; Labros Sidossis; Nicola Abate; Melinda Sheffield-Moore; Demidmaa Tuvdendorj
Journal:  Int J Dev Neurosci       Date:  2017-07-12       Impact factor: 2.457

2.  The interaction between ABCA1 polymorphism and physical activity on the HDL-cholesterol levels in a Japanese population.

Authors:  Yuichiro Nishida; Tsuyoshi Hachiya; Megumi Hara; Chisato Shimanoe; Keitaro Tanaka; Yoichi Sutoh; Atsushi Shimizu; Asahi Hishida; Mineko Tsukamoto; Yuka Kadomatsu; Isao Oze; Yuriko N Koyanagi; Nagato Kuriyama; Teruhide Koyama; Rie Ibusuki; Toshiro Takezaki; Hiroaki Ikezaki; Norihiro Furusyo; Naoyuki Takashima; Aya Kadota; Hirokazu Uemura; Sakurako Katsuura-Kamano; Sadao Suzuki; Hiroko Nakagawa-Senda; Kiyonori Kuriki; Haruo Mikami; Yohko Nakamura; Yukihide Momozawa; Michiaki Kubo; Masahiro Nakatochi; Mariko Naito; Kenji Wakai
Journal:  J Lipid Res       Date:  2019-11-06       Impact factor: 5.922

3.  Participation of white adipose tissue dysfunction on circulating HDL cholesterol and HDL particle size in apparently healthy humans.

Authors:  Juan G Juárez-Rojas; Ivan Torre-Villalvazo; Aida X Medina-Urrutia; Juan Reyes-Barrera; Víctor H Sainz-Escárrega; Carlos Posadas-Romero; Alejandro Macías-Cruz; Esteban Jorge-Galarza
Journal:  Int J Obes (Lond)       Date:  2019-12-02       Impact factor: 5.095

Review 4.  Current and future therapies for addressing the effects of inflammation on HDL cholesterol metabolism.

Authors:  Fatima Iqbal; Wendy S Baker; Madiha I Khan; Shwetha Thukuntla; Kevin H McKinney; Nicola Abate; Demidmaa Tuvdendorj
Journal:  Br J Pharmacol       Date:  2017-03-23       Impact factor: 8.739

5.  Targeting inflammation to reduce cardiovascular disease risk.

Authors:  Pasquale Maffia; Giuseppe Cirino
Journal:  Br J Pharmacol       Date:  2017-11       Impact factor: 8.739

6.  Capsaicin Supplementation Improved Risk Factors of Coronary Heart Disease in Individuals with Low HDL-C Levels.

Authors:  Yu Qin; Li Ran; Jing Wang; Li Yu; He-Dong Lang; Xiao-Lan Wang; Man-Tian Mi; Jun-Dong Zhu
Journal:  Nutrients       Date:  2017-09-20       Impact factor: 5.717

7.  Hot Water Extract of Curcuma longa L. Improves Serum Inflammatory Markers and General Health in Subjects with Overweight or Prehypertension/Mild Hypertension: A Randomized, Double-Blind, Placebo-Controlled Trial.

Authors:  Ryusei Uchio; Koutarou Muroyama; Chinatsu Okuda-Hanafusa; Kengo Kawasaki; Yoshihiro Yamamoto; Shinji Murosaki
Journal:  Nutrients       Date:  2019-08-07       Impact factor: 5.717

Review 8.  Functional Food and Bioactive Compounds on the Modulation of the Functionality of HDL-C: A Narrative Review.

Authors:  Karla Paulina Luna-Castillo; Sophia Lin; José Francisco Muñoz-Valle; Barbara Vizmanos; Andres López-Quintero; Fabiola Márquez-Sandoval
Journal:  Nutrients       Date:  2021-04-01       Impact factor: 5.717

Review 9.  Inflammation, not Cholesterol, Is a Cause of Chronic Disease.

Authors:  Alexandros Tsoupras; Ronan Lordan; Ioannis Zabetakis
Journal:  Nutrients       Date:  2018-05-12       Impact factor: 5.717

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.